EditorialPerspectives on early detection of chronic kidney disease: the facts, the questions, and a proposed framework for 2023 and beyond
Section snippets
The facts
Progress has been made in reducing the mortality and morbidity due to noncommunicable diseases, with the global age-standardized mortality rates between 2007 and 2017 for ischemic heart disease, stroke, and chronic obstructive pulmonary disease coming down by 9.7%, 13.6%, and 13.6%, respectively.1 However, the mortality rate due to CKD went up by 1.5% during the same period.1 Most of the future increase in CKD burden is projected to occur in LLMICs and among disadvantaged and indigenous
Disclosure
AL has received grant funding from GSK, Boehringer-Ingelheim-Lilly, National Institutes of Health (NIH), Canadian Institutes of Health Research (CIHR), AstraZeneca, Janssen, and Otsuka; and honoraria from Bayer and AstraZeneca, under the policy of all honoraria being paid to the institution/organization to support education and research activities. VJ has received grant funding from GSK, Baxter Healthcare, and Biocon; and honoraria from Bayer, AstraZeneca, Boehringer Ingelheim, NephroPlus, and
Acknowledgements
The authors are grateful to Dr. Priti Meena for developing Figure 1. AstraZeneca has provided a sponsorship grant to this independent program.
References (5)
- et al.
Early identification of chronic kidney disease—a scoping review of the global populations
Kidney Int Rep
(2022) - et al.
Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016
Kidney Int
(2018)